2 stocks I’d invest £1,000 in right now

If you are looking for decent share ideas, check out these two that reported on Thursday.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Public domain.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If mastering the art of investing boiled down to just crunching the numbers, I think picking up a few shares in speciality pharmaceuticals company Indivior (LSE: INDV) would be a ‘no-brainer’, to use the vernacular.

Indeed, the firm has a strong showing on quality and value metrics, and today’s full-year results update demonstrated further progress, with revenue 3% higher than a year ago and adjusted earnings per share at constant currency rates rising 5%. There’s a healthy net cash pile on the balance sheet of around $376m, up from $131m at the end of 2016, which is further evidence of the firm’s good trading. Chief executive Shaun Thaxter was optimistic about the outlook, saying in the report: “We face the future with enthusiasm and we are guiding to another year of top- and bottom-line growth in 2018.”

Be aware of the risks

However, investing in Indivior isn’t the ‘no-brainer’ that the quantitative information may suggest. There are significant risks that could end up blowing the business model out of the water, and a glance at the company’s risk statement is a sobering experience. The chief risk revolves around the fact that Indivior earns most of its income from one group of products for the treatment of opioid use disorder, branded with names such as Suboxone, and Sublocade in its various forms.

The firm has been trading well in the US where demand for addiction treatments is strong. But generic competition constantly threatens the enterprise, and there’s a depressingly long list of investigative and anti-trust litigation proceedings being undertaken against the company and by Indivior against competitors. The directors have raised the provision for investigative and antitrust litigation matters to $438m – ouch!

Diversification on the way

Yet there’s progress with product diversification. A product for the treatment of schizophrenia is set to launch at the end of 2018, and treatments for alcohol and stimulant use disorders are in the early stages of development. The stock dropped around 9% this morning, and while being aware of the risks, I’d be tempted to invest.

Meanwhile, global information and analytics provider Relx (LSE: REL) strikes me as a more-straightforward investment proposition and today’s full-year figures show continuing trading progress. Underlying revenue grew 4% during 2017 compared to the year before and constant currency adjusted earnings per share lifted 7%. The directors set the full-year dividend 10% higher, to top off what has been a great run for investors.

At today’s share price close to 1,441p, the stock has risen just over 100% over the past five years and the dividend is up more than 60% over that time. That’s a satisfactory investment outcome to me, but the stock seems to be falling now. I think this is a case of the stock being a victim of its own success. Although the outlook remains positive for the underlying business, I think momentum has carried the price a little too high and the valuation is correcting. I’d wait for the fall to base-out — which could be imminent — and then research the firm with a view to buying some of the shares because the enterprise looks like it has more growth left to run.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »